During this fiscal year, we reported that stathmin, a microtubule destabilizer required for the progression of cells through the cell cycle, also mediates the motility, migration, and invasion of malignant glioma cells. This was shown in experiments in which stathmin levels were experimentally increased or decreased with resulting changes in these cellular functions. We also demonstrated that nitrosoureas, DNA alkylating and protein carbamoylating drugs that inhibit stathmin and that are traditionally thought to inhibit only cell division, also inhibit motility, migration, and invasion. As invasion of surrounding brain by malignant glioma cells is one of the major causes of morbidity and mortality for patients with malignant glioma tumors, we are pursuing further strategies to inhibit stathmin function in vivo alone and in combination with nitrosourea therapy.
| Jarboe, John S; Johnson, Kory R; Choi, Yong et al. (2007) Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies. Cancer Res 67:7983-6 |
| Ngo, Teri-T B; Peng, Tien; Liang, Xing-Jie et al. (2007) The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas. J Natl Cancer Inst 99:639-52 |
| Akeju, Oluwaseun; Peng, Tien; Park, John K (2006) Short hairpin RNA loop design for the facilitation of sequence verification. Biotechniques 40:154, 156, 158 |
| Lee, Jeongwu; Kotliarova, Svetlana; Kotliarov, Yuri et al. (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9:391-403 |
| Purow, Benjamin W; Haque, Raqeeb M; Noel, Martha W et al. (2005) Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res 65:2353-63 |
